Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.

Ferris RG, Hazen RJ, Roberts GB, St Clair MH, Chan JH, Romines KR, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Weaver KL, Selleseth DW, Moniri KR, Boone LR.

Antimicrob Agents Chemother. 2005 Oct;49(10):4046-51.

2.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP.

Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6.

3.

Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell GS, Andrews CW 3rd, Reynolds DJ, St Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR.

J Med Chem. 2004 Feb 26;47(5):1175-82.

PMID:
14971897
4.

Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.

Portsmouth S, Imami N, Pires A, Stebbing J, Hand J, Nelson M, Gotch F, Gazzard BG.

HIV Med. 2004 Jan;5(1):26-9.

5.

New patterns of HIV-1 resistance during HAART.

Fumero E, Podzamczer D.

Clin Microbiol Infect. 2003 Nov;9(11):1077-84. Review.

6.

Drug resistance mutations in HIV-1.

D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD.

Top HIV Med. 2003 May-Jun;11(3):92-6. No abstract available.

7.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD.

Clin Infect Dis. 2003 Jul 1;37(1):113-28. Epub 2003 Jun 23.

PMID:
12830416
8.

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ.

Antimicrob Agents Chemother. 2003 Apr;47(4):1468-71.

9.

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5. Epub 2002 Oct 17.

10.
11.

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.

Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K.

Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84.

12.

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM.

Antimicrob Agents Chemother. 2000 Apr;44(4):920-8.

13.

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM.

N Engl J Med. 1999 Dec 16;341(25):1865-73.

14.

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.

Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 1999 Aug 20;13(12):1477-83.

PMID:
10465070
15.
16.

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR, Krenitsky TA.

Antimicrob Agents Chemother. 1997 May;41(5):1082-93.

18.

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.

Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D.

Nat Struct Biol. 1995 Apr;2(4):303-8.

PMID:
7540935
19.

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

Daluge SM, Purifoy DJ, Savina PM, St Clair MH, Parry NR, Dev IK, Novak P, Ayers KM, Reardon JE, Roberts GB, et al.

Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.

20.

Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, Hinuma Y.

Nature. 1981 Dec 24;294(5843):770-1. No abstract available.

PMID:
6275274

Supplemental Content

Support Center